Conclusion This classification system can be useful to accurately describe laryngoscopic findings during Ilo assessment. This system is now incorporated into our reporting practices to increase capture of Ilo diagnosis. The inclusion of supraglottic presentation with symptoms supports accurate diagnosis and treatment and further understanding of Ilo.

P23 PATIENT-REPORTED ONSET FACTORS IN INDUCIBLE LARYNGEAL OBSTRUCTION

¹C Slinger, ²R Slinger, ¹A Vyas. ¹Lancashire Teaching Hospitals, Preston, UK; ²Lancaster University, Lancaster, UK

10.1136/thoraxjnl-2017-210983.165

Introduction and Objectives Inducible Laryngeal Obstruction (Ilo) is poorly understood, in terms of aetiology and onset by patients and clinicians. Patients presenting to our Tertiary Airways service commonly seek an understanding of the causes and triggers of their Ilo episodes. This study aims to develop a taxonomy of categories of patient-reported onset factors for Ilo from a sample of patients with confirmed Ilo on laryngoscopy, referred to our service.

Method Within a nine month period, 103 patients referred to the Airways service (76% female, 24% male; age range 15–86 years (median=52)) with endoscopically-confirmed Ilo were asked to report historical factors contemporaneous with the initial onset of Ilo symptoms. A retrospective analysis of patient notes was also conducted to identify co-morbidities and additional onset factors. Single or multiple onset factors for each patient were collected, which were coded into initial themes. From these themes, second-order onset categories were developed which incorporated factors reported by all participants.

Results Thirteen initial onset themes were developed. These included psychological factors (25% of patients), upper respiratory tract infections (23%), reflux (17%), chest infections (14%), medical conditions (12%) and surgery (10%). These were then refined into a taxonomy of five categories of onset factors:

- Respiratory Tract Infections and Viruses (40% of patients)
- Underlying Medical Conditions, e.g., rhinitis with post nasal drip, reflux (34%)
- Psychological difficulties (25%)
- Irritants, e.g., medication (23%)
- Exercise (7%)

Only one patient had onset factors in multiple categories, indicating that these categories are largely independent of each other. The prevalence of certain onset factors was mediated to some degree by age, e.g., medical conditions were more frequent factors for older participants, whereas exercise was a more common factor in younger participants.

Conclusions This study demonstrates patient-reported onset factors for Ilo can be usefully translated into a detailed taxonomy based on specific conditions/triggers. This understanding may be useful in furthering our understanding, both of common trigger and onset factors that can be communicated to patients, and may help to inform therapeutic interventions aimed at the active self-management of Ilo.

Clinical update in COPD

P24 MAPPING OF END OF LIFE RECOGNITION AND PALLIATIVE CARE PROVISION IN COPD

¹HM Ward, ²A Wood, ³C Morrissey, ⁴F Hakkak. ¹The Royal Wolverhampton NHS Trust, Wolverhampton, UK; ²Graphnet Health Ltd, Milton Keynes, UK; ³Wolverhampton CCG, Wolverhampton, UK; ⁴Compton Hospice, Wolverhampton, UK

10.1136/thoraxjnl-2017-210983.166

COPD kills about 25 000 people per year in England and Wales (DoH 2011). NICE guidelines (2010) suggest patients with end stage COPD should have access to palliative services. The national COPD audit showed on-site palliative care provision has increased from 50% in 2008 to 87% in 2014 but less is known about out of hospital provision. The Gold Standard Framework (GSF) prognostic indicators assist clinicians to identify patients who are approaching end of life at an earlier stage enabling appropriate interventions to take place. These patients are more likely to receive well-coordinated and high quality care (GSF/RCGP 2011). The aim of our study was to map the number of QoF registered COPD patients, the frequency of COPD specific GSF indicators, the number included on primary palliative care registers (≥ 2 GSF prognostic indicators) and the number reviewed by palliative care.

Methods A multidisciplinary group with membership from CCG, acute trust, hospice and the community team oversaw the project. After a data sharing agreement was completed, data was collated from across all health care sites in our area for COPD patients enabling us to confirm the number and type of GSF prognostic indicators for each patient and health-care activity including palliative care reviews.

Results As of March 2016 there were 4999 COPD patients; 52% were male with an average age of 69.2 years. 25.7% of the patients (n=1285) had ≥ 1 GSF prognostic indicator. The most common indicator was MRC dyspnoea score of 4/5 (65.5%), followed by body mass index <20 (25.7%). Of the 294 patients with ≥ 2 GSF prognostic indicators 14.6% were on the GP palliative care register. 19.0% of the 294 patients had been reviewed by the palliative care team.

Conclusion GSF prognostic indicators in COPD are prevalent with breathlessness being the most common. Only a small proportion of appropriate patients were included on the palliative care register (14.6%) with more being seen by palliative care teams than on the registers. Further work is needed to ensure effective communication and education is provided across the whole health care system to identify patients earlier who are approaching end of life.

P25 LIVING WITH COPD: A PUBLIC AWARENESS AND SCREENING CAMPAIGN

¹MG Crooks, ²J Thompson, ³S Platten, ⁴C Evans, ²S Faruqi. ¹Hull York Medical School, Hull, UK; ²Hull and East Yorkshire Hospitals NHS Trust, Hull, UK; ³City Health Care Partnership, Hull, UK; ⁴British Lung Foundation, London, UK

10.1136/thoraxjnl-2017-210983.167

Background Chronic Obstructive Pulmonary Disease (COPD) is a smoking related lung disease characterised by airflow obstruction on spirometry. COPD patients are prone to acute exacerbations, frequently leading to health care utilisation. There are over 7500 people in Hull with COPD and it is estimated over 6000 patients are living with the condition without a diagnosis. Early identification of COPD with targeted smoking cessation and early initiation of treatment has potential to improve outcomes. We describe the early Results of a COPD screening initiative in Hull.

Methods A collaborative screening program was developed involving the acute hospital trust, community services, clinical commissioning group and city council. The initiative was supported by British Lung Foundation, branded under their 'Love Your Lungs' campaign. Screening was undertaken over 4 days in public venues in areas with high smoking prevalence. Individuals completed symptom and lifestyle questionnaires and FEV-1/FEV-6 assessment. Symptomatic individuals with FEV-1 $\leq$ 80% predicted and/or FEV-1/FEV-6 ratio $<$ 0.73 were invited to attend a one-stop clinic where they underwent diagnostic spirometry and saw a respiratory physician and smoking cessation specialist.

Results 253 individuals were screened (41% male, 25% current smokers). 67/253 screened positive and 60 were given a one-stop clinic appointment. Individuals not offered appointments either declined or lived outside the area. 31/60 individuals attended their appointment, 6/60 are awaiting review and 23/60 either cancelled or did not attend (DNA). 17/31 clinic attenders were diagnosed with COPD and 13/31 received an alternative diagnosis in addition to or instead of COPD. 57/60 were discharged for on-going care under their GP and 3/60 remain under specialist follow-up. The characteristics of screen positive individuals are presented in Table 1.

Conclusions In this unselected screening program, the COPD diagnosis rate was 7% and would likely have been higher if all screen positive individuals had attended a one-stop clinic. This compares favourably with diagnosis rates in targeted COPD case finding trials reported previously. Engaging current smokers proved challenging with high DNA rates in this group. Further research is required to assess whether early COPD diagnosis through screening alters smoking behaviour or disease outcomes.

Abstract P25 Table 1 Characteristics of screen positive individuals

Value	Screen Positive	Clinic Attenders	Confirmed COPD
Number	67	31	17
Age (years) – mean (SD)	60.5 (13)	62.4 (13)	63.3 (13.1)
Smoking Status – n (%)			
- Current	21 (31)	6 (19)	3 (18)
- Ex	33 (49)	16 (52)	11 (65)
- Never	10 (15)	6 (19)	0 (0)
- Unknown	3 (4)	3 (10)	3 (17.6)
Pack Year – mean(SD)	28.4 (25.2)	25.6 (28.4)	41.1 (31.8)
CAT Score – mean (SD)	17.3 (9.5)	18.2 (10)	19.1 (11.5)
Screening Spirometry – mean (SD)			
- FEV-1 (L) / % predicted	1.8 (0.6) / 70.4 (17.5)	1.8 (0.7) / 66.6 (16.4)	1.8 (0.7) / 65.4 (18.8)
- FEV-6 (L)	2.5 (0.9)	2.4 (1.0)	2.7 (1.0)
- Ratio	0.76 (0.11)	0.74 (0.12)	0.66 (0.10)
Diagnostic Spirometry –mean (SD)	-	1.9 (0.7) / 68.5 (20.8)	1.9 (0.7) / 68.4 (16.3)
- FEV-1 (L) / % predicted	-	2.9 (1.1) / 86.8 (17.9)	3.2 (1.1) / 91.9 (15.7)
- FVC (L) / % predicted	-	0.67 (0.13)	0.60 (0.11)
- Ratio	17 (25.4)	17 (55)	-
Confirmed COPD – n (%)	13 (19.4)	13 (42)	-
Other diagnosis – n (%)			-